T‑Cells from HLA-B57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms
Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to...
Saved in:
Published in | Chemical research in toxicology Vol. 26; no. 5; pp. 759 - 766 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
20.05.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself. |
---|---|
AbstractList | Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself.Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself. Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different V beta receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself. Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01. HLA-B*57:01-restricted activation of CD8+ T-cells provides a link between the genetic association and the iatrogenic disease. The objectives of this study were to characterize the functionality of drug-responsive CD8+ T-cell clones generated from HLA-B*57:01+ drug-naive subjects and to explore the relationship between abacavir accumulation in antigen presenting cells and the T-cell response. Seventy-four CD8+ clones expressing different Vβ receptors were shown to proliferate and kill target cells via different mechanisms when exposed to abacavir. Certain clones were activated with abacavir in the absence of antigen presenting cells. Analysis of the remaining clones revealed two pathways of drug-dependent T-cell activation. Overnight incubation of antigen presenting cells with abacavir, followed by repeated washing to remove soluble drug, activated approximately 50% of the clones, and the response was blocked by glutaraldehyde fixation. In contrast, a 1 h antigen presenting cell pulse did not activate any of the clones. Accumulation of abacavir in antigen presenting cells was rapid (less than 1 h), and the intracellular concentrations were maintained for 16 h. However, intracellular abacavir was not detectable by mass spectrometry after pulsing. These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules. With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction. In contrast, the latter pathway likely involves MHC binding peptides displayed as a consequence of abacavir exposure, but not abacavir itself. |
Author | Naisbitt, Dean J Farrell, John Alfirevic, Ana Park, B. Kevin Pirmohamed, Munir Bell, Catherine C Faulkner, Lee Martinsson, Klara Tugwood, Jonathan |
AuthorAffiliation | University of Liverpool The University of Manchester |
AuthorAffiliation_xml | – name: University of Liverpool – name: The University of Manchester |
Author_xml | – sequence: 1 givenname: Catherine C surname: Bell fullname: Bell, Catherine C – sequence: 2 givenname: Lee surname: Faulkner fullname: Faulkner, Lee – sequence: 3 givenname: Klara surname: Martinsson fullname: Martinsson, Klara – sequence: 4 givenname: John surname: Farrell fullname: Farrell, John – sequence: 5 givenname: Ana surname: Alfirevic fullname: Alfirevic, Ana – sequence: 6 givenname: Jonathan surname: Tugwood fullname: Tugwood, Jonathan – sequence: 7 givenname: Munir surname: Pirmohamed fullname: Pirmohamed, Munir – sequence: 8 givenname: Dean J surname: Naisbitt fullname: Naisbitt, Dean J – sequence: 9 givenname: B. Kevin surname: Park fullname: Park, B. Kevin email: bkpark@liv.ac.uk |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23541086$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-96946$$DView record from Swedish Publication Index |
BookMark | eNqF0ktv1DAQAGALFdEHHPgDyBckEIRO7DiP3sIW2EpbgcSCuFmO43S9SuLgR5e98RcQ_5Bfglfb9oAqcbEP8834MXOMDkYzKoSepvAmBZKe-h8ZAOQwPUBHKSOQMEjhAB1BWdGEkPLbITp2bg2QRl48QoeEsiyFMj9Cv5d_fv6aqb53uLNmwPNFnbxlxRmkr_A8DGLEn0OzVtI7XFuFa-n1tfCqxRvtV7huhBTX2mK_siZcrfByY_DF2KpJxWX0-JPwq43YOizGdhcIUuHdafhcxQhutvgy9F5PvcKXSq7EqN3gHqOHneidenKzn6Av798tZ_Nk8fHDxaxeJIKWzCeN7BqAouiaHDqZtaxljEpS0lJWknSKCegUqRrSiiwj0JCOgigEKQVtJWVAT9DrfV23UVNo-GT1IOyWG6H5uf5ac2OveK8Dr_IqyyN_seeTNd-Dcp4P2sn4GDEqExyPP5_RihVx_S-ljGZFHlsV6bMbGppBtXeXuG1RBKd7IK1xzqqOS-2F12b0Vuiep8B3Q8DvhiBmvPwn47boffb53grp-NoEO8Yfv8f9BYvfvio |
CitedBy_id | crossref_primary_10_1021_acs_chemrestox_2c00090 crossref_primary_10_1021_acs_chemrestox_9b00327 crossref_primary_10_1021_acs_chemrestox_6b00333 crossref_primary_10_1016_j_toxlet_2013_10_036 crossref_primary_10_1016_j_iac_2014_04_009 crossref_primary_10_1111_all_14127 crossref_primary_10_1111_all_15814 crossref_primary_10_1038_s42003_021_02657_2 crossref_primary_10_1111_cea_14423 crossref_primary_10_1371_journal_pcbi_1009151 crossref_primary_10_1016_j_coi_2016_05_003 crossref_primary_10_1007_s00204_017_2112_9 crossref_primary_10_1093_toxsci_kfz007 crossref_primary_10_1093_toxsci_kfw177 crossref_primary_10_1146_annurev_pharmtox_052120_014115 crossref_primary_10_1021_acs_chemrestox_4c00262 crossref_primary_10_1111_all_14057 crossref_primary_10_1093_toxsci_kfaa157 crossref_primary_10_1016_j_tox_2021_152971 crossref_primary_10_1111_all_13769 crossref_primary_10_1097_ACI_0000000000000913 crossref_primary_10_1021_ol4036566 crossref_primary_10_1097_ACI_0000000000000834 crossref_primary_10_3987_COM_15_13350 crossref_primary_10_1155_2018_5163129 crossref_primary_10_1093_toxsci_kfw218 crossref_primary_10_4049_jimmunol_1302306 crossref_primary_10_1080_17425255_2018_1441285 crossref_primary_10_1080_03602532_2020_1800725 crossref_primary_10_1155_2016_9520361 crossref_primary_10_1172_JCI99321 crossref_primary_10_1021_acs_chemrestox_6b00393 crossref_primary_10_1039_C4CC06632D crossref_primary_10_1021_tx400406p crossref_primary_10_3389_fimmu_2020_01037 crossref_primary_10_1097_QAD_0000000000000867 crossref_primary_10_1111_tan_13183 crossref_primary_10_3389_fimmu_2021_658593 crossref_primary_10_1248_yakushi_21_00120 crossref_primary_10_1021_tx400041v crossref_primary_10_1016_j_dmpk_2016_11_003 crossref_primary_10_1080_2162402X_2018_1538436 crossref_primary_10_1016_j_biopha_2023_115241 crossref_primary_10_1517_17425255_2015_992780 crossref_primary_10_1007_s00044_023_03091_1 crossref_primary_10_1039_C4TX00238E crossref_primary_10_1111_cea_14235 crossref_primary_10_1016_j_jdermsci_2017_08_007 crossref_primary_10_1097_DAD_0000000000000439 |
Cites_doi | 10.1086/504874 10.1038/ng.379 10.1038/sj.tpj.6500458 10.1021/pr100967v 10.4049/jimmunol.1003409 10.1073/pnas.0307067101 10.1073/pnas.261581498 10.1016/j.jaci.2009.10.031 10.1002/eji.201142159 10.1097/00002030-200501030-00014 10.1016/S0149-2918(01)80132-6 10.1007/BF03256308 10.1371/journal.pone.0028323 10.1097/00002030-200211080-00017 10.1097/QAD.0b013e328355fe8f 10.1016/S0009-2797(02)00059-5 10.1073/pnas.1207934109 10.1038/ng.632 10.1038/nature11147 10.1056/NEJMoa1009717 10.1177/135965350801300202 10.1038/428486a 10.1186/gm350 10.1111/j.1600-065X.2012.01147.x 10.1016/j.immuni.2008.04.020 10.1016/j.jaci.2006.12.617 10.1056/NEJMoa0706135 10.1073/pnas.0409500102 10.1016/S0140-6736(02)07873-X |
ContentType | Journal Article |
Copyright | Copyright © 2013 American Chemical Society |
Copyright_xml | – notice: Copyright © 2013 American Chemical Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7U7 C1K ADTPV AOWAS DG8 |
DOI | 10.1021/tx400060p |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Toxicology Abstracts Environmental Sciences and Pollution Management SwePub SwePub Articles SWEPUB Linköpings universitet |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE - Academic Toxicology Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-5010 |
EndPage | 766 |
ExternalDocumentID | oai_DiVA_org_liu_96946 23541086 10_1021_tx400060p a039200216 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Medical Research Council grantid: G0700654 |
GroupedDBID | - 29B 4.4 55A 5GY 5RE 7~N AABXI ABFLS ABMVS ABPTK ABUCX ACGFS ACJ ACS AEESW AENEX AFEFF ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 EBS ED ED~ EJD F5P GNL IH9 IHE JG JG~ LG6 P2P ROL TN5 UI2 UPT VF5 VG9 W1F X YZZ --- -~X 5VS AAYXX ABBLG ABJNI ABLBI ABQRX ADHLV AGXLV AHGAQ BAANH CITATION CUPRZ GGK CGR CUY CVF ECM EIF NPM 7X8 7U7 C1K .GJ .HR 1WB 53G ABHMW ACRPL ADNMO ADTPV AEYZD AGQPQ ANPPW ANTXH AOWAS DG8 RNS ZGI |
ID | FETCH-LOGICAL-a385t-bcfb0077fb60fc4d5d553c2838c9c2fe5a0fe29b2da4420b2f30a7a28a3dc3503 |
IEDL.DBID | ACS |
ISSN | 0893-228X 1520-5010 |
IngestDate | Thu Aug 21 06:30:19 EDT 2025 Fri Jul 11 02:41:58 EDT 2025 Fri Jul 11 01:45:56 EDT 2025 Mon Jul 21 05:30:34 EDT 2025 Thu Apr 24 22:51:24 EDT 2025 Tue Jul 01 03:45:20 EDT 2025 Thu Aug 27 13:42:09 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a385t-bcfb0077fb60fc4d5d553c2838c9c2fe5a0fe29b2da4420b2f30a7a28a3dc3503 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 23541086 |
PQID | 1353476520 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | swepub_primary_oai_DiVA_org_liu_96946 proquest_miscellaneous_1524395724 proquest_miscellaneous_1353476520 pubmed_primary_23541086 crossref_citationtrail_10_1021_tx400060p crossref_primary_10_1021_tx400060p acs_journals_10_1021_tx400060p |
ProviderPackageCode | JG~ 55A AABXI GNL VF5 7~N ACJ VG9 W1F ACS AEESW AFEFF ABMVS ABUCX IH9 AQSVZ ED~ UI2 CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-05-20 |
PublicationDateYYYYMMDD | 2013-05-20 |
PublicationDate_xml | – month: 05 year: 2013 text: 2013-05-20 day: 20 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Chemical research in toxicology |
PublicationTitleAlternate | Chem. Res. Toxicol |
PublicationYear | 2013 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | Chessman D. (ref9/cit9) 2008; 28 Lu J. V. (ref27/cit27) 2012; 249 Wu Y. (ref15/cit15) 2007; 119 Thomas D. A. (ref24/cit24) 2001; 98 Martin A. M. (ref18/cit18) 2005; 19 Chung W. H. (ref17/cit17) 2004; 428 Adam J. (ref11/cit11) 2012; 42 Walsh J. S. (ref29/cit29) 2002; 141 Chang C. P. (ref28/cit28) 2011; 6 Mallal S. (ref3/cit3) 2002; 359 Phillips E. (ref4/cit4) 2009; 13 Mallal S. (ref2/cit2) 2008; 358 Norcross M. A. (ref13/cit13) 2012; 26 Hung S. I. (ref19/cit19) 2005; 102 Illing P. T. (ref12/cit12) 2012; 486 Almeida C. A. (ref6/cit6) 2008; 13 Saini R. V. (ref25/cit25) 2011; 186 Hetherington S. (ref1/cit1) 2001; 23 Ostrov D. A. (ref10/cit10) 2012; 109 Singer J. B. (ref21/cit21) 2010; 42 Schmidt H. (ref26/cit26) 2011; 10 Rauch A. (ref5/cit5) 2006; 43 Kindmark A. (ref22/cit22) 2008; 8 Martin A. M. (ref7/cit7) 2004; 101 Daly A. K. (ref20/cit20) 2009; 41 Chen P. (ref23/cit23) 2011; 364 Alfirevic A. (ref14/cit14) 2012; 4 Phillips E. J. (ref8/cit8) 2002; 16 Castrejon J. L. (ref16/cit16) 2010; 125 |
References_xml | – volume: 43 start-page: 99 year: 2006 ident: ref5/cit5 publication-title: Clin. Infect. Dis. doi: 10.1086/504874 – volume: 41 start-page: 816 year: 2009 ident: ref20/cit20 publication-title: Nat. Genet. doi: 10.1038/ng.379 – volume: 8 start-page: 186 year: 2008 ident: ref22/cit22 publication-title: Pharmacogenomics J. doi: 10.1038/sj.tpj.6500458 – volume: 10 start-page: 1603 year: 2011 ident: ref26/cit26 publication-title: J. Proteome Res. doi: 10.1021/pr100967v – volume: 186 start-page: 3497 year: 2011 ident: ref25/cit25 publication-title: J. Immunol. doi: 10.4049/jimmunol.1003409 – volume: 101 start-page: 4180 year: 2004 ident: ref7/cit7 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0307067101 – volume: 98 start-page: 14985 year: 2001 ident: ref24/cit24 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.261581498 – volume: 125 start-page: 411 year: 2010 ident: ref16/cit16 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2009.10.031 – volume: 42 start-page: 1706 year: 2012 ident: ref11/cit11 publication-title: Eur. J. Immunol. doi: 10.1002/eji.201142159 – volume: 19 start-page: 97 year: 2005 ident: ref18/cit18 publication-title: AIDS doi: 10.1097/00002030-200501030-00014 – volume: 23 start-page: 1603 year: 2001 ident: ref1/cit1 publication-title: Clin Ther. doi: 10.1016/S0149-2918(01)80132-6 – volume: 13 start-page: 1 year: 2009 ident: ref4/cit4 publication-title: Mol. Diagn. Ther. doi: 10.1007/BF03256308 – volume: 6 start-page: e28323 year: 2011 ident: ref28/cit28 publication-title: PLoS One doi: 10.1371/journal.pone.0028323 – volume: 16 start-page: 2223 year: 2002 ident: ref8/cit8 publication-title: AIDS doi: 10.1097/00002030-200211080-00017 – volume: 26 start-page: 21 year: 2012 ident: ref13/cit13 publication-title: AIDS doi: 10.1097/QAD.0b013e328355fe8f – volume: 141 start-page: 135 year: 2002 ident: ref29/cit29 publication-title: Chem. Biol. Interact. doi: 10.1016/S0009-2797(02)00059-5 – volume: 109 start-page: 9959 year: 2012 ident: ref10/cit10 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.1207934109 – volume: 42 start-page: 711 year: 2010 ident: ref21/cit21 publication-title: Nat. Genet. doi: 10.1038/ng.632 – volume: 486 start-page: 554 year: 2012 ident: ref12/cit12 publication-title: Nature doi: 10.1038/nature11147 – volume: 364 start-page: 1126 year: 2011 ident: ref23/cit23 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1009717 – volume: 13 start-page: 281 year: 2008 ident: ref6/cit6 publication-title: Antiviral Ther. doi: 10.1177/135965350801300202 – volume: 428 start-page: 486 year: 2004 ident: ref17/cit17 publication-title: Nature doi: 10.1038/428486a – volume: 4 start-page: 51 year: 2012 ident: ref14/cit14 publication-title: Genome Med. doi: 10.1186/gm350 – volume: 249 start-page: 205 year: 2012 ident: ref27/cit27 publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2012.01147.x – volume: 28 start-page: 822 year: 2008 ident: ref9/cit9 publication-title: Immunity doi: 10.1016/j.immuni.2008.04.020 – volume: 119 start-page: 973 year: 2007 ident: ref15/cit15 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2006.12.617 – volume: 358 start-page: 568 year: 2008 ident: ref2/cit2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0706135 – volume: 102 start-page: 4134 year: 2005 ident: ref19/cit19 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0409500102 – volume: 359 start-page: 727 year: 2002 ident: ref3/cit3 publication-title: Lancet doi: 10.1016/S0140-6736(02)07873-X |
SSID | ssj0011027 |
Score | 2.3020258 |
Snippet | Susceptibility to abacavir hypersensitivity has been attributed to possession of the specific human leukocyte antigen allele HLA-B*57:01.... |
SourceID | swepub proquest pubmed crossref acs |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 759 |
SubjectTerms | CD8-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology Cell Death - drug effects Cell Line Cell Proliferation Clone Cells - cytology Clone Cells - drug effects Clone Cells - immunology Cytokines - immunology Dideoxynucleosides - chemistry Dideoxynucleosides - pharmacology Dose-Response Relationship, Drug HLA-B Antigens - immunology Humans Leukocytes, Mononuclear - cytology Leukocytes, Mononuclear - immunology Lymphocyte Activation - drug effects Structure-Activity Relationship |
Title | T‑Cells from HLA-B57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms |
URI | http://dx.doi.org/10.1021/tx400060p https://www.ncbi.nlm.nih.gov/pubmed/23541086 https://www.proquest.com/docview/1353476520 https://www.proquest.com/docview/1524395724 https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-96946 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3bbtQwELVKeUFCFMptKVTDrUKiaZOxnQtvYZdqQSxaiW21b5HtONKqS7Zqsm2XJ34B8Yd8CXaSTYGW8uyJJlHO2McezxlCXlAqAuGJwNGhFdWmTDpCGyLHAhQh19pLM1vgPPjk9_fZhzEfr5Dn_8jgo7dbnrFKNeToGrmOvgley3-6n9tUgTGq5Twj6iCG46V80O-P2qVHFX8uPRf45F9iodUCs7dGessynfpeyeHOvJQ76utF1car3v02udUQTIhrRNwhKzpfJ1vDWqF6sQ2j84KrYhu2YHiuXb1YJzfrYzyoq5Pukh-jn9--d_V0WoAtRIH-x9h5y4M3rvcaqvN_MDOPPcopjEcNsaq6pekU7PkuxFIocTI5hqYbEIxOZ_C-bbxbwtDwz1OxKEDkqR0wOAPrDXqWmYJcwKC58AgDbWuUJ8WX4h7Z33s36vadpo-DI2jIS0eqTFrZoEz6bqZYylPOqTK8JlSRwkxz4WYaI4mpYAxdiRl1DYIwFDRVlLv0PlnNZ7l-SEBh4CvPTDJ24xRQGqVSSFdRs0kNMoz8Dtk0Pzpp4rBIqhQ7ekn7Izrk1RIDiWpU0G0zjullps9a06Na-uMyo6dLICUmMG22ReR6NjeuKacs8Dm6V9hwZDZRiqxDHtQobF0h5cy2weqQlzUs2xGrCN6bHMSJgVoyncyTyI-Y_-h_n75BbmDVy4ObqfExWS2P5_qJYVSl3Kwi6hdSbRsc |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZgPIA0cRkwymUcEExILCPxJRfeQsfUQTtVokN9i2zHkSpKOs0pozzxFxD_kF-C7aQpjAl49klsy5_tYx-f70PoCSE84gGPPBVbUm1ChceVceRohHnMlArywiY4Dw7D3hF9M2bjhibH5sKYRmjzJ-2C-Ct2geBF9Zk68pDji-iScUKwRXPafddGDIxRzeqZEA_jeLxkEfr1U7sDSf37DvSHW3mGM9TtM_vXasEi10L3vOTD7rwSu_LLGfLG_-vCdXS1cTchrfFxA11Q5QbaHtZ81YsdGK3Sr_QObMNwxWS92EDr9aUe1LlKN9H30Y-v37pqOtVg01Kg10-9Vyx66QfPwUUDwKxD9mJHmxoVpNJpp6kc7G0vpIJL_mlyAo02EIxOZ3DQyvBWMDTe6ClfaOBlbgsM6sDWBnvWTwWxgEHz_BEGymYsT_RHfQsd7b8edXteo-rgcRKzyhOyEJZEqBChX0ias5wxIo2XE8tE4kIx7hcKJwLnnFLsC1wQ3-AJx5zkkjCf3EZr5axUdxBIHIUyMEuOPUZFhCS54MKXxBxZowInYQdtmXHImlmpMxdwx0HWDkQHPVtCIZMNJ7qV5pieZ_q4NT2uiUDOM3q0xFNmpqmNvfBSzeamasIIjQxu_b_YMExt2BTTDtqswdhWhQmjVhSrg57W6GxLLD_43uR9mhm4ZdPJPEvChIZ3_9X1h-hybzToZ_2Dw7f30BXsVD6YWTTvo7XqZK4eGF-rEltukv0EVhUjfQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwELZgSAhp4mXAKC_jQDAhsYzEL3nhW2ipOlhHpXWo3yLbcaSK0lZLyiif-AuIf8gvwZekGYwJ-OxLzpafs88-33OEPGFMBtKTgWNCJNVmXDnSWEeOB1SGwhgvzTDBuX_g9474m5EY1QdFzIWxncjtn_IyiI9WPU-zmmHAe1F85iWByPwiuYThOkR03D5sogZWqGL2jJhDaThaMQn9-inuQjr_fRf6w7U8wxta7jXda-Rd08vyicmH3UWhdvWXMwSO_z-M6-Rq7XZCXOHkBrlgphtke1DxVi93YHiahpXvwDYMThmtlxtkvbrcgypn6Sb5Pvzx9VvbTCY5YHoK9PZj55UIXrrecyijAmDXI7zgya1GA7Eua6iZFPDWF2Iltfw0Poa6RhAMT2aw15TjLWBgvdITucxBTlNssOgD1AYd9FdBLaFfP4OEvsHM5XH-Mb9Fjrqvh-2eU1d3cCQLReEonSkkE8qU72aapyIVgmnr7YQ60jQzQrqZoZGiqeScuopmzLW4oqFkqWbCZbfJ2nQ2NXcIaBr42rNLDx6nAsaiVEnlamaPrkFGI79FtuxcJLV15kkZeKde0kxEizxbwSHRNTc6luiYnCf6uBGdV4Qg5wk9WmEqseaKMRg5NbOFVc0E44EvqPsXGUE5hk8pb5HNCpCNKsoEx-JYLfK0QmjTgjzhnfH7OLGQSybjRRL5Effv_mvoD8nlQaeb7O8dvL1HrtCy2Iewa-d9slYcL8wD63IVaqu0s5-0-CYA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=T-cells+from+HLA-B57&rft.jtitle=Chemical+research+in+toxicology&rft.au=Bell%2C+Catherine+C.&rft.au=Faulkner%2C+Lee&rft.au=Martinsson%2C+Klara&rft.au=Farrell%2C+John&rft.date=2013-05-20&rft.issn=0893-228X&rft.volume=26&rft.issue=5&rft.spage=759&rft_id=info:doi/10.1021%2Ftx400060p&rft.externalDocID=oai_DiVA_org_liu_96946 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-228X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-228X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-228X&client=summon |